Haemostatix’s innovative technology platform is based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of soluble or solid carriers to create both topical and systemic haemostats.

Haemostatix's topical haemostat, PeproStat, is composed of multiple peptides coupled to a soluble carrier, thus forming a highly active fibrinogen-binding site. When sprayed onto blood, the product polymerises fibrinogen to form a fibrin-like clot, without the need for thrombin. It can also be added to purified fibrinogen to form an exogenous clot or ‘seal’ over a wound. This new mode of action, based on peptide:protein recognition, is significantly quicker compared to the enzymic action of thrombin, resulting in improved control of bleeding.  More...

In the systemic formulation, the peptide is coupled to microparticles and, when administered, the peptide binds the patient’s own fibrinogen and this targets the microparticle to the formation of a clot at a wound site. The clot is completed by conversion of fibrinogen into fibre-like fibrin by the enzyme thrombin. The targeted peptide-microparticle physically augments clot formation, acting as a platelet substitute. The systemic formulation is the basis of the company’s product HaemoPlax, being developed for the prevention of bleeding in leukaemic, thrombocytopenic patients. More...

In addition to coupling the fibrinogen binding peptide to different supports or carrier proteins, Haemostatix has also modified the peptide sequence to create a ‘pro-drug’ version of HaemoPlax, HXTC 901, in which the peptide sequence is protected and only activated by thrombin at a wound site. More... 

This targeted approach to creating clotting materials at wound sites is the key to the success of Haemostatix’s products. Each of the three products within the current pipeline is designed to treat or prevent different forms of bleeding .